Back to Search
Start Over
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
- Source :
-
Asia Pacific Journal of Clinical Oncology . Oct2017, Vol. 13 Issue 5, pe189-e194. 6p. - Publication Year :
- 2017
-
Abstract
- Aim Elevated neutrophil-to-lymphocyte ratio ( NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor ( EGFR)-mutated advanced non-small-cell lung cancer ( NSCLC) patients treated with first-line EGFR tyrosine kinase inhibitors ( TKIs) is not fully addressed. Methods 81 metastatic NSCLC patients harboring EGFR mutation treated with first-line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. Results Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression-free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P < 0.001 and 17.20 vs 23.20 months, P < 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression-free and overall survival in Cox multivariate analysis. Conclusion Elevated NLR is likely to be associated with poor outcome in EGFR-mutated advanced NSCLC patients treated with first-line EGFR TKIs. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17437555
- Volume :
- 13
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Asia Pacific Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 125929586
- Full Text :
- https://doi.org/10.1111/ajco.12273